The inventors have discovered that heart disease may be treated with Apolipoprotein D (ApoD), a 169 residue, 29 kDa glycoprotein member of the lipocalin family that binds to several ligands, including progesterone and arachidonic acid, and is associated with HDL in plasma. It is expressed highly in nervous tissue and overexpressed in aging, neurological and psychiatric disorders.
Dendrimers have been used as effective drug delivery vehicles due to their ability to enter cells and escape the endosome; however they are associated with high levels of toxicity and an inability to distinguish between healthy cells and tumor cells. In order to overcome this drawback, the inventors conjugated the dendrimer with a synthetic epidermal growth factor (EGFR) binding peptide to provide breast cancer cell targeting for efficient delivery of chemotherapeutic drugs.
This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
This technology describes the precise protein combinations needed for different types of neuron cell development. It illustrates which proteins are necessary and which ones are sufficient. It accomplishes this through standard biochemical methods such as retroviral transduction, in ovo electroporation, immunocytochemistry, and in situ hybridization histochemistry.
Facile method allows direct observation of effect of force with much higher throughput than other methods. Other methods to apply force to proteins, such as AFM or optical tweezers, are limited by the difficulty of setting up experiments and the time to complete an analysis. Additionally, these instruments are very expensive and difficult to operate and maintain. This method allows for multiple measurements to be conducted at the same time, greatly increasing the rate of experiments that can be conducted by a single researcher.
HAUSP (herpesvirus-associated ubiquitin-specific protease) as a novel p53-interacting deubiquitinase. HAUSP strongly stabilizes p53 by deubiquitinating p53, even in the presence of excess Mdm2. In addition, HAUSP binds directly to Mdm2 in such a way as to form a three-protein complex with p53 and, via this indirect interaction, p53 is also stabilized. The technology provides methods for screening HAUSP-p53 and HAUSP-Mdm2 interactions.
The invention identified two polypeptides comprising a given segment of continuous amino acids or at least two of each covalently linked to each other. These polypeptides activate the DNA binding activity of p53 and thus activate the cellular functions of p53, enable their use as pharmaceutical compositions in a variety of therapeutic regimens, which permits the arrest of the growth or proliferation of tumor cells or apoptosis of tumor cells.